AbbVie/J&J's Imbruvica On Track For New Indication In Graft-Versus-Host Disease
Results suggest 67% objective response rate in second-line+ chronic graft versus host disease; Phase III study is already testing Imbruvica for new onset disease.
Results suggest 67% objective response rate in second-line+ chronic graft versus host disease; Phase III study is already testing Imbruvica for new onset disease.